Skip to main content

Table 2 Predictive performance (and 95% confidence interval) of the DLDA30 predictor in patients treated with preoperative chemotherapy

From: CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

  Breast tumors of any phenotype HER-2-positive breast tumors
Performance metrics Validation cohort
T/FACa
n = 51
Present study cohort
Trastuzumab + T/FEC
n = 45
Subset of validation cohort
T/FACa
n = 30
Area under the curve 0.877 (0.066) 0.565 (0.089) 0.81 (0.092)
Overall accuracy 0.76 (0.62–0.87) 0.51 (0.36–0.66) 0.67 (0.47–0.83)
Sensitivity 0.92 (0.64–1.00) 0.52 (0.33–0.71) 0.90 (0.56–1.00)
Specificity 0.71 (0.54–0.85) 0.50 (0.25–0.75) 0.55 (0.32–0.77)
Positive predictive value 0.52 (0.31–0.73) 0.65 (0.43–0.84) 0.50 (0.26–0.74)
Negative predictive value 0.96 (0.82–1.00) 0.36 (0.17–0.59) 0.92 (0.62–1.00)
  1. aHess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. [17]. T/FAC, paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide; T/FEC, paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide.